Peter Ganea – författare

This thoroughly revised second edition presents a comprehensive assessment of the revised patent law and related secondary legislation in the People’s Republic of China (PRC). It examines the latest policy and patent law related aspects in Greater China to reveal valuable insights into the evolving legal landscape. Highly experienced professionals in the field provide practical guidance on the latest practices in technology transfer, patent prosecution, the reformed employee inventions system in the PRC and patent litigation.Key Features:Evaluates China’s latest patent policy and strategyGives important insights on the latest developments concerning substantive patent law, as well as PCT and national patent application proceduresAnalyzes emerging issues around standard-essential patents which are gaining traction in an increasingly globalized systemExplores developments in patent law in relation to specific areas, such as the pharmaceutical industry, as well as software- and AI-related inventionsDraws on extensive case law to shed light on claims interpretation and patent enforcement issues, including infringement and invalidation proceedings, dual enforcements by courts and administrative authoritiesExplains the latest developments in utility model and design protectionCovers the latest patent system developments in the Special Administrative Regions of Hong Kong, Macao and Chinese Taipei, encompassing the entire Greater China region This updated edition of Patent Law in Greater China is an essential resource for lawyers, patent attorneys and other practitioners, as well as policymakers active in the region with an interest in the broader context of patents as key intellectual property rights in an increasingly technology driven world.

Regenerative Medizin setzt große Hoffnungen in die Forschung mit humanen embryonalen Stammzellen. Ebenso umstritten wie diese Forschung selbst ist auch die Patentierung von Erfindungen, die sich auf humane embryonale pluripotente Stammzellen beziehen. Sowohl im regulatorischen Bereich wie auch im Bereich der Patentierung gibt es international große Unterschiede. Die Beiträge legen dar und analysieren die aus rechtlicher wie ethischer Sicht komplizierte Rechtslage der Patentierung in diesem Bereich nach dem europäischen Patent-recht und den Patentrechten der VR China, Deutschlands, Frankreichs, Japans, Kanadas, Koreas, Österreichs, der Schweiz, der USA und des Vereinigten Königreiches. Jedem an dieser Materie Interessierten bieten sie eine wertvolle Orientierungshilfe.